Full Press Release Details
New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan. The results underscore MCS-8’s previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in prostate cancer prevention, showing its potential in helping alleviate high-grade malignancy risk. The data reveals significant new value in metabolic indicators, specifically cholesterol and lactate dehydrogenase (LDH). Building on this momentum, the Company is evaluating the feasibility of expanding MCS-8’s indications to include lipid management, atherosclerosis, and cardiovascular diseases—a strategic move aimed at extending the product’s lifecycle and significantly capturing a broader market share.
The Phase II clinical trial demonstrated that after two years of treatment, subjects receiving MCS-8 showed improved lipid control compared with baseline, including:
LDH is an enzyme widely present in organs and tissues throughout the body, and elevated serum LDH levels are commonly associated with cellular damage or cell death. The absence of LDH elevation in the MCS-8 group suggests that MCS-8 may not be causing damage or death to the cell.
As previously disclosed, the primary efficacy endpoint of the Phase II study showed that, compared with placebo, the MCS-8 group demonstrated a 27.3% reduction in overall prostate cancer incidence. In addition, the incidence of high-grade prostate cancer (Total Gleason Score ≥ 7) was reduced by 17.1% compared with placebo. Further pathological analyses demonstrated favorable trends, including a 35.2% reduction in the percentage of positive cores involved at diagnosis and a 24.4% reduction in the percentage of cancer-positive area involved in positive cores, compared with placebo, suggesting improved control of disease progression. Safety data from the previously disclosed analyses showed that long-term administration of MCS-8 for two years did not increase the rate of adverse events. No serious adverse events related to MCS-8 were observed, and no negative effects were identified on liver function, kidney function, or blood pressure. Company believes that the favorable tolerability profile supports the potential suitability of MCS-8 for long-term preventive use.
MCS-8 is developed using Jyong Biotech’s core patented pharmaceutical composition technology, which Company believes significantly enhances bioavailability and improves physiological efficacy, offering substantial potential for the development of multiple dosage forms and indications.
Related research findings have been published in the international journalNanotechnologyand included by Global Medical Discovery institutions in Canada.
MCS-8 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction.
About Jyong Biotech Ltd.
Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.
For more information, please visit:https://www.jyongbio.com/,https://jyongir.com/.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review atwww.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.